Markers of detection
- PMID: 17628306
- DOI: 10.1016/j.urolonc.2007.05.012
Markers of detection
Abstract
Three applications of markers of detection: screening, replacing surveillance cystoscopies, and guiding evaluation of asymptomatic hematuria, are discussed. In one study, repetitive hematuria screening in men age >or=50 effectively shifted the stage of high grade cancers at diagnosis from muscle invasive to earlier ones, reducing bladder cancer, and all cause mortality. This technique is sensitive, but is not terribly specific. Testing other markers alone or in combination with each other and/or hemoglobin screening in similar or higher risk populations is now beginning. Currently, no commercially available marker is sufficiently sensitive to replace all surveillance cystoscopies for low risk bladder cancer, although some cystoscopic examinations can probably be replaced by markers. Available markers are too insensitive for small, high grade cancers to replace any surveillance cystoscopies in this group. No single marker or combination of markers can safely replace cystoscopy in the work-up of patients with microhematuria who are at high risk for harboring bladder cancer. However, markers may be useful for directing which patients age <or=40 with asymptomatic microhematuria without histories of smoking, particularly women, require cystoscopic evaluation.
Similar articles
-
Feasibility study of screening for bladder cancer with urinary molecular markers (the BLU-P project).Urol Oncol. 2010 Nov-Dec;28(6):686-90. doi: 10.1016/j.urolonc.2009.12.002. Urol Oncol. 2010. PMID: 21062653 Clinical Trial.
-
Characterization of the DD23 tumor-associated antigen for bladder cancer detection and recurrence monitoring. Marker Network for Bladder Cancer.Cancer Epidemiol Biomarkers Prev. 1996 Dec;5(12):971-8. Cancer Epidemiol Biomarkers Prev. 1996. PMID: 8959319
-
Molecular markers in bladder cancer: a critical appraisal.Urol Oncol. 2006 Jul-Aug;24(4):326-37. doi: 10.1016/j.urolonc.2005.11.023. Urol Oncol. 2006. PMID: 16818187 Review.
-
Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers.Urology. 2005 Dec;66(6 Suppl 1):35-63. doi: 10.1016/j.urology.2005.08.064. Urology. 2005. PMID: 16399415
-
Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer.J Clin Oncol. 2006 Dec 10;24(35):5528-35. doi: 10.1200/JCO.2006.08.0895. J Clin Oncol. 2006. PMID: 17158538 Review.
Cited by
-
FGFR3b Extracellular Loop Mutation Lacks Tumorigenicity In Vivo but Collaborates with p53/pRB Deficiency to Induce High-grade Papillary Urothelial Carcinoma.Sci Rep. 2016 May 9;6:25596. doi: 10.1038/srep25596. Sci Rep. 2016. PMID: 27157475 Free PMC article.
-
UroSEEK gene panel for bladder cancer surveillance.Transl Androl Urol. 2019 Dec;8(Suppl 5):S546-S549. doi: 10.21037/tau.2019.12.41. Transl Androl Urol. 2019. PMID: 32042643 Free PMC article. No abstract available.
-
Biomarkers to assess the risk of bladder cancer in patients presenting with haematuria are gender-specific.Front Oncol. 2022 Sep 23;12:1009014. doi: 10.3389/fonc.2022.1009014. eCollection 2022. Front Oncol. 2022. PMID: 36212463 Free PMC article.
-
Potential new urinary markers in the early detection of bladder cancer.Curr Opin Urol. 2009 Sep;19(5):488-93. doi: 10.1097/MOU.0b013e32832eb3a0. Curr Opin Urol. 2009. PMID: 19584734 Free PMC article. Review.
-
Immune checkpoint blockade therapy for bladder cancer treatment.Investig Clin Urol. 2016 Jun;57 Suppl 1(Suppl 1):S98-S105. doi: 10.4111/icu.2016.57.S1.S98. Epub 2016 May 26. Investig Clin Urol. 2016. PMID: 27326412 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical